Payment overview · 2025
General Payments
$616.72
26 reported records · 12 companies
Healthcare provider profile · identity verified
Leonid Volfinzon, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1952403933
Verified facts
What the public records show
CMS Open Payments records show Leonid Volfinzon, M.D. received $616.72 in general payments during 2025 across 26 reported records.
ABBVIE INC. accounted for 32.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess, Ozempic, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 255 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 292 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $197.61 | 32.0% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $65.74 | 10.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.17 | 10.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $58.50 | 9.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.76 | 7.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $47.82 | 7.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.52 | 4.6% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $24.29 | 3.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.97 | 3.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $22.08 | 3.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.50 | 3.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.76 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $616.72 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $144.86 | 7 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $65.74 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $63.17 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $58.50 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $52.75 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $52.75 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $48.76 | 2 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $47.82 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.21 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.42 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.52 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 86 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 139 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 126 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 131 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 77 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
86 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
131 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
255 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
46 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
139 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
126 | 20 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
292 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
77 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 804 | 130 |
| Metoprolol Succinate | Metoprolol Succinate | 763 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 736 | 128 |
| Losartan Potassium | Losartan Potassium | 708 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 610 | 96 |
| Metformin Hcl | Metformin Hcl | 416 | 70 |
| Diclofenac Sodium | Diclofenac Sodium | 385 | 66 |
| Omeprazole | Omeprazole | 385 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 380 | 65 |
| Famotidine | Famotidine | 321 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 294 | 39 |
| Eliquis | Apixaban | 292 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 272 | 50 |
| Synthroid | Levothyroxine Sodium | 255 | 30 |
| Gabapentin | Gabapentin | 252 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 251 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 250 | 35 |
| Furosemide | Furosemide | 206 | 34 |
| Carvedilol | Carvedilol | 196 | 28 |
| Dexlansoprazole Dr | Dexlansoprazole | 189 | 22 |
| Ezetimibe | Ezetimibe | 188 | 30 |
| Glimepiride | Glimepiride | 188 | 28 |
| Vascepa | Icosapent Ethyl | 184 | 27 |
| Simvastatin | Simvastatin | 176 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 27 |
| Meloxicam | Meloxicam | 158 | 32 |
| Lisinopril | Lisinopril | 150 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 148 | 24 |
| Spironolactone | Spironolactone | 145 | 26 |
| Nebivolol Hcl | Nebivolol Hcl | 142 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 141 | 18 |
| Farxiga | Dapagliflozin Propanediol | 139 | 27 |
| Allopurinol | Allopurinol | 135 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 131 | 14 |
| Linzess | Linaclotide | 131 | 19 |
| Ranolazine Er | Ranolazine | 129 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 127 | 31 |
| Jardiance | Empagliflozin | 126 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 24 |
| Valsartan | Valsartan | 115 | 12 |
| Tradjenta | Linagliptin | 110 | 13 |
| Lidocaine | Lidocaine | 109 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 107 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 23 |
| Donepezil Hcl | Donepezil Hcl | 106 | 18 |
| Finasteride | Finasteride | 102 | 15 |
| Trulicity | Dulaglutide | 101 | 18 |
| Enalapril Maleate | Enalapril Maleate | 98 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 24 |
| Januvia | Sitagliptin Phosphate | 95 | 15 |
| Telmisartan | Telmisartan | 95 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 92 | 19 |
| Potassium Chloride | Potassium Chloride | 89 | 14 |
| Creon | Lipase/Protease/Amylase | 86 | 17 |
| Nifedipine Er | Nifedipine | 86 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 82 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 80 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 27 |
| Mounjaro | Tirzepatide | 78 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 15 |
| Ammonium Lactate | Ammonium Lactate | 76 | 14 |
| Atenolol | Atenolol | 70 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 65 | 12 |
| Entresto | Sacubitril/Valsartan | 65 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 64 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 61 | 17 |
| Propranolol Hcl | Propranolol Hcl | 60 | 11 |
| Buspirone Hcl | Buspirone Hcl | 58 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 58 | 17 |
| Dapagliflozin | Dapagliflozin Propanediol | 58 | 14 |
| Ibuprofen | Ibuprofen | 58 | 29 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 57 | suppressed |
| Torsemide | Torsemide | 57 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 56 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 56 | suppressed |
| Repatha Sureclick | Evolocumab | 56 | suppressed |
| Azithromycin | Azithromycin | 53 | 47 |
| Montelukast Sodium | Montelukast Sodium | 52 | suppressed |
| Bystolic | Nebivolol Hcl | 50 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 48 | 11 |
| Celecoxib | Celecoxib | 48 | suppressed |
| Dexilant | Dexlansoprazole | 48 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 48 | suppressed |
| Myrbetriq | Mirabegron | 47 | 11 |
| Prolia | Denosumab | 46 | 28 |
| Propranolol Hcl Er | Propranolol Hcl | 46 | suppressed |
| Nitroglycerin | Nitroglycerin | 45 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 44 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 44 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 11 |
| Edarbi | Azilsartan Medoxomil | 42 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 41 | suppressed |
| Eszopiclone | Eszopiclone | 41 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 41 | suppressed |
| Clotrimazole | Clotrimazole | 40 | 15 |
| Lansoprazole | Lansoprazole | 39 | suppressed |
| Nexium | Esomeprazole Magnesium | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Hydrocortisone | Hydrocortisone | 37 | 11 |
| Meclizine Hcl | Meclizine Hcl | 37 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 21 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 35 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Febuxostat | Febuxostat | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | 14 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 33 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 33 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Benicar | Olmesartan Medoxomil | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 25 | 11 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | suppressed |
| Acarbose | Acarbose | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | 11 |
| Donepezil Hcl Odt | Donepezil Hcl | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | 14 |
| Digoxin | Digoxin | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Proctozone-Hc | Hydrocortisone | 16 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Cefadroxil | Cefadroxil | 15 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 15 | 13 |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Prednisone | Prednisone | 15 | 14 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Mupirocin | Mupirocin Calcium | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Zetia | Ezetimibe | 13 | suppressed |
| Zileuton Er | Zileuton | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Micardis | Telmisartan | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Avapro | Irbesartan | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Qbrexza | Glycopyrronium Tosylate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $616.72 · 26 records | ABBVIE INC. | CAMZYOS, CREON, FARXIGA, IBSRELA, JARDIANCE, LAGEVRIO, LINZESS, OTEZLA, Ozempic, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY, UNITHROID, XIFAXAN, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error